U.S. FDA Revokes COVID-19 Emergency Use Authorization forChloroquine and Hydroxychloroquine
June 15, 2020Zepzelca Approved to Treat Small Cell Lung Cancer
June 15, 2020Juvéderm Voluma XC Granted New Cosmetic Indication
June 15, 2020 – The U.S. FDA has approved a new indication for Juvéderm® VolumaTM XC (hyaluronic acid), manufactured by Allergan Aesthetics, for augmentation of the chin region to improve the chin profile in adults over the age of 21. The product is the first and only filler approved by the FDA for this purpose.
In a clinical study, Juvéderm Voluma XC was found to be safe and effective for augmentation of the chin. The majority of participants reported high satisfaction throughout one year of follow up. The product is injected by a healthcare professional trained in its use, with effects lasting for up to two years. It is only available by prescription.
Juvederm Voluma XC first received FDA approval in 2013 for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face.
